It is believed that releasing the extracellular domain of syndecan-1 from the intestinal epithelial cells may reduce the intensity of inflammatory bowel diseases and the transmigration of neutrophils by inactivating key inflammatory mediators and reducing the expression of proinflammatory cytokines. The gene discussed is SDC1; the disease is inflammatory bowel disease.